Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer
Last Updated: Wednesday, January 27, 2021
This study prospectively assessed comprehensive next-generation sequencing of cell-free circulating tumor DNA (cfDNA) compared with standard-of-care tissue-based testing and found that cfDNA assay is noninferior to tissue testing in identifying targetable alterations.
Advertisement
News & Literature Highlights